Comparative Pharmacology
Head-to-head clinical analysis: QUINACT versus QUINAGLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINACT versus QUINAGLUTE.
QUINACT vs QUINAGLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
Class Ia antiarrhythmic agent; binds to sodium channels and inhibits the fast inward sodium current, slowing phase 0 depolarization and prolonging the action potential duration. Also exhibits anticholinergic and negative inotropic effects.
100 mg orally three times daily.
324-648 mg orally every 8-12 hours; extended-release formulation (quinidine gluconate).
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Terminal elimination half-life is 5-7 hours in adults with normal renal function. In hepatic impairment, half-life may increase to 12-24 hours; in severe renal impairment (CrCl <10 mL/min), half-life may exceed 24 hours.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of total clearance. Biliary/fecal excretion contributes about 20-30%. Acidic urine increases renal clearance.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)